

1. **OPINION PIECE: [A major gain from US elections would be the collapse of TPP that threatens India's export prospects](#) – The Times of India**

Whatever be the final outcome of the US presidential election in early November one thing that is certain is that India will end up a major gainer. This is because, despite all their differences, one thing that both the democrats and republicans, have in common is their agreement to jettison the Trans-Pacific Partnership (TPP), the giant mega regional preferential trade agreement (PTA) of Pacific Rim countries that has been so painstakingly concluded up by the Obama administration. This would not only increase the costs that exporters have to incur for confirming with the new bench

marks but it might even require India to further tighten its regulations in areas like protection of intellectual property rights which would impair on the India's pharmaceutical industry.

1. [OPINION PIECE: A major gain from US elections would be the collapse of TPP that threatens India's export prospects](#) – The Times of India
2. [More cancer, HIV drugs to cost less post price cap](#) – The Economic Times
3. [Over 1 lakh patents filed since 2013](#) – Mint
4. [Suven Life Sciences bags 2 patents](#) – The Hindu Business
5. [Rajya Sabha passes bills to put in place NEET](#) – Business Standard
6. [Chemists not to keep Schedule H1 drugs](#) – The Hindu
7. [National Dialysis Programme: Private participation opens up new vista in healthcare space](#) – The Indian Express
8. [OPINION PIECE: A lot 'Left' to be done in American politics](#) – Hindustan Times
9. [Debate on e-pharmacy by leaders of pharma trade and civic associations evokes mixed responses](#) – Pharmabiz.com

2. **[More cancer, HIV drugs to cost less post price cap](#) – The Economic Times**

The National Pharmaceutical Pricing Authority (NPPA) has slashed by up to 35% prices of several essential medicines, including those to treat cancers and HIV infections. In its latest notification, the drug pricing watchdog has capped price of antibiotic doxycycline (100mg) and revised ceiling prices of 23 medicines already included in the National List of Essential Medicines (NLEM). Patients should see a drop between 10% and 35% in the prices of these medicines, NPPA told ET.

*Also appeared in-*

- [NPPA cuts drug prices of cancer, HIV, cardiac by 25%](#) - The Hindu Business Line
- [NPPA cuts prices of cancer, HIV, cardiac drugs by around 25%](#) - Mint
- [Pharma pricing authority slashes rates of cancer, HIV, cardiac drugs by 25%](#) - Hindustan Times
- [Cancer, HIV drugs to become cheaper: NPPA](#) – The New Indian Express
- [Cancer, HIV, cardiac drugs get cheaper](#) – Deccan Herald

3. **[Over 1 lakh patents filed since 2013](#) – Mint**

Data from the Indian Controller General of Patents, Designs and Trade Marks shows that a total of 1, 45,060 patents were filed between 2013 and 20 July 2016. Of this, Indian citizens or organizations account for 39,318 while the number is 1, 05,742 for foreign nationals and organizations. Of the 12,442 applications filed in 2016-17 (up to 20 July), 3,248 are Indian applicants and 9,194 are of foreign origin. A total of 16,004 patents were filed by Indian natural persons (individuals) when compared to 3,900 patents filed by foreign nationals in the same period.

4. [Suven Life Sciences bags 2 patents – The Hindu Business Line](#)  
Suven Life Sciences Ltd has secured two patents, one each from Macau and New Zealand, corresponding to its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven which are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's, and Schizophrenia, among others, the Hyderabad-based company said in a release issued here on Monday.
5. [Rajya Sabha passes bills to put in place NEET – Business Standard](#)  
The Rajya Sabha on Monday passed by voice vote the Indian Medical Council (Amendment) Bill, 2016, and the Dentists (Amendment) Bill, 2016, that provide for putting the NEET in place for admission to medical and dental courses across the country from next year. The bills provide for a Constitutional status to the 'National Eligibility-cum-Entrance Test (NEET) and seek to amend the Indian Medical Council Act, 1956, and the Dentists Act, 1948. Responding to a debate on the bills in the Rajya Sabha, Minister of Health and Family Welfare Jagat Prakash Nadda said the whole exercise was aimed to stop multiplicity of examinations, to bring transparency to curb corruption and to stop exploitation of students.
6. [Chemists not to keep Schedule H1 drugs – The Hindu](#)  
Drug stores in the State have decided not to store any of the Schedule H 1 drugs till a decision is taken by the government to stop the "illegal" raids by the Excise Department. In a press meet held here on Monday, the All Kerala Chemists and Druggists Association (AKCDA) said the association had decided not to keep 46 drugs in the Schedule H 1 list because of which the Excise Department was conducting the raids. The Schedule H 1 drugs cannot be sold over the counter without the prescription of a registered medical practitioner.
7. [National Dialysis Programme: Private participation opens up new vista in healthcare space – The Indian Express](#)  
It has been a while now that public private partnerships (PPPs) have been a buzzword in India's infrastructure sector but despite a clear roadmap in the 12th five year plan, PPP has largely been a dirty word in healthcare. It was for the first time in the ambulance service and later to some extent in diagnostics that India dabbled in PPP in healthcare, but when finance minister Arun Jaitley in his Budget speech spoke about a National Dialysis Programme in PPP mode, he made a commitment that had implications beyond health in the realm of governance.
8. **OPINION PIECE:** [A lot 'Left' to be done in American politics – Hindustan Times](#)  
In Philadelphia last week, Hillary Clinton was confirmed as the first female presidential candidate to represent a major party in American history. At the same time, a much unlikelier bid for the White House officially came to an end. Bernie Sanders tested the bounds of plausibility in his race against Clinton, winning over 40% of the Democratic national primary vote. It's hardly a surprise that Sanders — a humourless, self-described "socialist" of Jewish heritage — failed to beat one of the most powerful and determined figures in American politics. But the tremendous support he received is a sign of deeper political changes in the country.
9. [Debate on e-pharmacy by leaders of pharma trade and civic associations evokes mixed responses – Pharmabiz.com](#)  
Mixed responses have come up in a deliberation held on the scope of online trade of medicines (e-pharmacy) in the Indian scenario by the pharma captains and representatives of civic associations in Chennai last week. The deliberation was in the form of a debate between two panels of supporters of online pharmacy and off-line pharmacy, and the subject was, 'Online Pharmacy – Needed or Not-needed'. The panel who supported online sale of drugs represented pharmacy academia, clinical research association and media. Those opposed were from wholesale trade, pharmacy council and consumer awareness group. There was no representation from the retail sector, regulatory side and manufacturing industry.